Beyond Martin Shkreli’s behavior,the price of medications pits the interests of patients against the profits of two big industries – pharmaceuticals and insuranceUntil this week most of us had never heard of Daraprim, a drug that fights toxoplasmosis. But after the decision of the drugs fresh owner, or Turing Pharmaceuticals,to boost its cost per pill from $13.50 to a whopping $750, we’re all unlikely to forget its name or the name of Turing’s owner, or 32-year-used Martin Shkreli.
Shkreli became one of the most hated men in America last week,Hillary Clinton called for reforms in the drug market, social media tore him to shreds, and a punk label he bankrolled severed ties with him and even Donald Trump weighed in,calling him a “spoiled brat”.
Continue reading...
Source: theguardian.com